Dr. Schmidt on the Utilization of Bispecific Antibodies in Myeloma

Video

Timothy M. Schmidt, MD, discusses the utilization of bispecific antibodies in myeloma.

Timothy M. Schmidt, MD, an assistant professor of the Department of Medicine at the University of Wisconsin School of Medicine and Public Health, discusses the utilization of bispecific antibodies in myeloma.

Bispecific antibodies are a promising off-the-shelf treatment option that have been developed to engage the immune system in patients with relapsed/refractory multiple myeloma or other hematologic malignancies, according to Schmidt. Similar to CAR T-cell therapies, bispecific products activate T cells and bring them in close proximity of cancer cells; this allows the agent to recognize when cells are abnormal and induce cell death, concludes Schmidt.

Related Videos
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Saad Z. Usmani, MD, MBA, FACP, FASCO, chief, Myeloma Service, Memorial Sloan Kettering Cancer Center
Francesco Di Meo, PhD
Hans Lee, MD, associate professor, director, Multiple Myeloma Clinical Research, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Saad Z. Usmani, MD, MBA, FACP, FASCO, chief, Myeloma Service, Memorial Sloan Kettering Cancer Center
Danai Dima, MD
Krina K. Patel, MD, MSc, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Ariel Grajales-Cruz, MD, assistant member, Department of Malignant Hematology, Multiple Myeloma Section, Moffitt Cancer Center; assistant professor, University of South Florida
Rachid Baz, MD, section head, Myeloma, Department of Malignant Hematology, Moffitt Cancer Center; co-director, Pentecost Family Myeloma Research Center
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic